Breaking News, Collaborations & Alliances

Bayer, Thermo Fisher Partner to Advance Access to Precision Cancer Medicines

Aims to develop next-gen sequencing companion diagnostics to help increase patient access to precision cancer therapies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bayer AG and Thermo Fisher Scientific Inc. partnered to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) to help identify patients who may benefit from Bayer’s precision cancer therapies by offering decentralized genomic testing and rapid turnaround time. Financial terms were not disclosed.    The CDx will be developed using Thermo Fisher’s Oncomine Dx Express Test on the Ion Torrent Genexus Dx System, a fully integrated NGS platform that can deliver results on ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters